Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
The University of Texas MD Anderson Cancer Center · National Institutes of Health · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
335
total citations
- FWCI
- 39.94
- Percentile
- 100%
- References
- 47
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Trametinib
- Dabrafenib
- Medicine
- Anaplastic thyroid cancer
- Internal medicine
- Cohort
- Oncology
- Progression-free survival
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.